European Society for Medical Oncology (ESMO)

First-Line CDK4/6 Inhibitors Plus Aromatase Inhibitors: Treatment Duration and Subsequent Therapies in HR-Positive/HER2-Negative Metastatic Breast Cancer

This real-world study examines the role of ovarian function suppression as adjuvant therapy in hormone receptor (HR)-positive/HER2-positive premenopausal breast cancer patients who achieved pathologic complete response following neoadjuvant chemotherapy, analyzing its use within routine clinical practice. Read More ›

Adjuvant Abemaciclib + Endocrine Therapy in High-Risk HR-Positive/HER2-Negative Early Breast Cancer: Positive Primary Overall Survival Outcomes From monarchE

This study examines treatment duration and patterns of follow-up therapies after first-line cyclin-dependent kinase (CDK)4/6 inhibitor plus aromatase inhibitor use in hormone receptor (HR)-positive/HER2-negative metastatic breast cancer in US clinical practice. Read More ›

Reduced Risk of Recurrence Scoring After Neoadjuvant Ribociclib Plus Endocrine Therapy in High-Risk ER-Positive/HER2-Negative Breast Cancer: Preliminary Results From the SOLTI-RIBOLARIS Trial

Updated results from the monarchE trial indicate positive primary overall survival outcomes of adjuvant abemaciclib combined with endocrine therapy in hormone receptor (HR)-positive/HER2-negative high-risk early breast cancer. Read More ›

5-Year Follow-Up Results From the POSITIVE Trial: Successful Pregnancy Outcomes and Safety of Endocrine Therapy Interruption in Endocrine-Responsive Breast Cancer

A preliminary analysis of the SOLTI-RIBOLARIS trial shows reduced recurrence risk in high-risk estrogen receptor (ER)-positive/HER2-negative breast cancer patients treated with neoadjuvant ribociclib and endocrine therapy, highlighting recurrence dynamics and potential clinical benefits. Read More ›

5-Year Results From NATALEE Demonstrate Sustained Effect: Evaluating Ribociclib + NSAIs in HR-Positive/HER2-Negative Early Breast Cancer

The POSITIVE trial’s 5-year follow-up reports favorable pregnancy outcomes and does not appear to increase the risk of breast cancer recurrence at 5 years in women with endocrine-responsive breast cancer. Read More ›

The 5-year landmark analysis of the NATALEE trial highlights sustained improvements with adjuvant ribociclib combined with nonsteroidal aromatase inhibitors (NSAIs) for hormone receptor (HR)-positive/HER2-negative early breast cancer. Read More ›

Combined Efficacy and Safety Data From 2 Phase 2 Trials of Taletrectinib in Patients Diagnosed With Advanced or Metastatic ROS1-Positive NSCLC

Safety and efficacy data evaluating taletrectinib in patients diagnosed with advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC) were reported from the TRUST-I and TRUST-II phase 2 studies. Read More ›

TROPION-Lung01: Datopotamab Deruxtecan (Dato-DXd) in Combination With Docetaxel (DTX) in Patients With Advanced Nonsquamous NSCLC With Brain Metastases

The TROPION-Lung01 trial found a significant improvement in progression-free survival when comparing Dato-DXd to DTX in patients with advanced non-small cell lung cancer (NSCLC), particularly those with nonsquamous histology. Read More ›

GFPC 03-2019: A Comprehensive National Analysis of the Management of Patients With ROS1-Positive Metastatic NSCLC

The Explore ALK/ROS study investigated the management practices and clinical outcomes of patients with advanced non-small cell lung cancer (NSCLC) who tested positive for ROS1. Read More ›

Comprehensive Genomic Profiling Enables Patients to Access Innovative Matched Therapies Within a Varied Real-World Cohort of Patients Suffering From Advanced Lung Cancer